Sepracor Isomer of J&J Propulsid Could Expand Indications

Janssen will fund investigation of Sepracor's norcisapride, a single-isomer version of the Johnson & Johnson subsidiary's Propulsid (cisapride), for bulimia, emesis and irritable bowel syndrome, as well as for Propulsid's current indication in gastroesophogeal reflux disease, Sepracor CEO Timothy Barberich reported in a July 21 conference call.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet